128 related articles for article (PubMed ID: 12926825)
1. Hepatitis C: a review of diagnosis, management, and ocular complications from treatment.
Tsolakos A; Zalatimo N
Optometry; 2003 Aug; 74(8):517-23. PubMed ID: 12926825
[TBL] [Abstract][Full Text] [Related]
2. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
Burgueño-Montañés C; Pérez-Álvarez R
Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.
Okuse C; Yotsuyanagi H; Nagase Y; Kobayashi Y; Yasuda K; Koike K; Iino S; Suzuki M; Itoh F
World J Gastroenterol; 2006 Jun; 12(23):3756-9. PubMed ID: 16773695
[TBL] [Abstract][Full Text] [Related]
4. Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C.
Adams S; Ostermeier M
Optometry; 2010 Nov; 81(11):580-6. PubMed ID: 20655283
[TBL] [Abstract][Full Text] [Related]
5. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin.
Schulman JA; Liang C; Kooragayala LM; King J
Ophthalmology; 2003 Feb; 110(2):437-42. PubMed ID: 12578794
[TBL] [Abstract][Full Text] [Related]
6. [Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C].
Nakamura T; Takahashi H; Koike N; Mitsutaka M; Soda M; Kimu M
Nippon Ganka Gakkai Zasshi; 2005 Nov; 109(11):748-52. PubMed ID: 16363669
[TBL] [Abstract][Full Text] [Related]
7. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
Kim ET; Kim LH; Lee JI; Chin HS
Jpn J Ophthalmol; 2009 Nov; 53(6):598-602. PubMed ID: 20020238
[TBL] [Abstract][Full Text] [Related]
8. [Interferon-related retinopathy in a man with chronic hepatitis C].
Viennet A; Glatre F; Bacin F
J Fr Ophtalmol; 2009 Sep; 32(7):505-10. PubMed ID: 19592135
[TBL] [Abstract][Full Text] [Related]
9. Interferon-induced retinopathy and its risk in patients with diabetes and hypertension undergoing treatment for chronic hepatitis C virus infection.
Panetta JD; Gilani N
Aliment Pharmacol Ther; 2009 Sep; 30(6):597-602. PubMed ID: 19549263
[TBL] [Abstract][Full Text] [Related]
10. [Interferon dysoric retinopathy in chronic viral hepatitis C: case report and literature review].
Naïja N; Mohsni B; Belkahla N; Maamouri N; Ben Mami N
Rev Med Interne; 2014 Aug; 35(8):543-5. PubMed ID: 24182682
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin.
Fouad YM; Khalaf H; Ibraheem H; Rady H; Helmy AK
Int J Infect Dis; 2012 Jan; 16(1):e67-71. PubMed ID: 22115957
[TBL] [Abstract][Full Text] [Related]
12. Retinal nerve fibre layer defects associated with cotton-wool spots in patients with interferon retinopathy.
Hara K; Tanito M; Ohira A
Acta Ophthalmol; 2012 Mar; 90(2):e158-60. PubMed ID: 21649866
[No Abstract] [Full Text] [Related]
13. Is screening for interferon retinopathy in hepatitis C justified?
Cuthbertson FM; Davies M; McKibbin M
Br J Ophthalmol; 2004 Dec; 88(12):1518-20. PubMed ID: 15548803
[TBL] [Abstract][Full Text] [Related]
14. Outcome of retinopathy in chronic hepatitis C patients treated with peginterferon and ribavirin.
Mehta N; Murthy UK; Kaul V; Alpert S; Abruzzese G; Teitelbaum C
Dig Dis Sci; 2010 Feb; 55(2):452-7. PubMed ID: 19242801
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening.
Vujosevic S; Tempesta D; Noventa F; Midena E; Sebastiani G
Hepatology; 2012 Aug; 56(2):455-63. PubMed ID: 22331668
[TBL] [Abstract][Full Text] [Related]
16. Ophthalmologic findings in hepatitis C patients treated with pegylated interferon α-2b and ribavirin.
Novelli FJ; Przysiezny A; Rosa EL; Garcia RF; Nóbrega MJ
Arq Bras Oftalmol; 2014; 77(3):178-81. PubMed ID: 25295906
[TBL] [Abstract][Full Text] [Related]
17. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis.
Marrache F; Consigny Y; Ripault MP; Cazals-Hatem D; Martinot M; Boyer N; Degott C; Valla D; Marcellin P
J Viral Hepat; 2005 Jul; 12(4):421-8. PubMed ID: 15985014
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
20. Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection.
Shen Y; Pielop J; Hsu S
Arch Dermatol; 2005 Jan; 141(1):102-3. PubMed ID: 15655158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
